These findings provide robust evidence that SLC7A11 overexpression protects against dopaminergic neurodegeneration and associated motor deficits in diabetic rats with 6‐OHDA‐induced parkinsonism, highlighting its potential as a therapeutic strategy for PD patients with comorbid diabetes. This evidence concerns the gene SLC7A11 and Parkinson disease.